Literature DB >> 27219465

Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial.

F Orio1,2, G Muscogiuri3, F Giallauria4, S Savastano5, P Bottiglieri6, D Tafuri7, P Predotti6, G Colarieti8, A Colao5, S Palomba9.   

Abstract

BACKGROUND: Although oral contraceptives (OCs) are one the most widespread therapy in young polycystic ovary syndrome (PCOS) women and physical exercise represents a crucial first step in the treatment of overweight and obese PCOS, no studies were performed to compare the effects on cardiovascular risk (CVR) of OCs and physical exercise in PCOS.
OBJECTIVE: To compare the effects of OCs administration and physical exercise on the CVR, clinical, hormonal and metabolic parameters in PCOS women.
METHODS: One hundred and fifty PCOS women were enrolled and were randomized to OCs (3 mg drospirenone plus 30 μg ethinyloestradiol), structured exercise training programme (SETP) or polyvitamin tablets. The intervention phase study was of 6 months. Primary outcome was intima-media thickness (IMT) and flow-mediated dilation (FMD). Secondary outcomes were clinical, hormonal and metabolic changes.
RESULTS: A significant reduction of IMT and a significant increase of FMD were observed in the SETP group after treatment. Compared to baseline, in the SETP group, a significant improvement in anthropometric measures, insulin sensitivity indexes, lipid profile, cardiopulmonary function, inflammatory markers and frequency of menses was observed. Oral contraceptives use was associated with a significant decrease of hyperandrogenism and a significant improvement of frequency of menses. Further, OCs use had a neutral effect on CVR risk factors.
CONCLUSION: OCs effectively treat hyperandrogenism and menstrual disturbances, while SETP is more effective in improving cardiometabolic profile and cardiopulmonary function in PCOS.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27219465     DOI: 10.1111/cen.13112

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  17 in total

1.  Heat therapy improves glucose tolerance and adipose tissue insulin signaling in polycystic ovary syndrome.

Authors:  Brett R Ely; Zachary S Clayton; Carrie E McCurdy; Joshua Pfeiffer; Karen Wiedenfeld Needham; Lindan N Comrada; Christopher T Minson
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-05-28       Impact factor: 4.310

2.  Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.

Authors:  Sonali S Patel; Uyen Truong; Martina King; Annie Ferland; Kerrie L Moreau; Jennifer Dorosz; John E Hokanson; Hong Wang; Gregory L Kinney; David M Maahs; Robert H Eckel; Kristen J Nadeau; Melanie Cree-Green
Journal:  Vasc Med       Date:  2017-01-17       Impact factor: 3.239

3.  Exercise Recommendations for Women with Polycystic Ovary Syndrome: Is the Evidence Enough?

Authors:  Nigel K Stepto; Rhiannon K Patten; Eliza C Tassone; Marie L Misso; Leah Brennan; Jacqueline Boyle; Russell A Boyle; Cheryce L Harrison; Angelica Lindén Hirschberg; Kate Marsh; Alba Moreno-Asso; Leanne Redman; Mala Thondan; Chandrika Wijeyaratne; Helena J Teede; Lisa J Moran
Journal:  Sports Med       Date:  2019-08       Impact factor: 11.136

4.  Lifestyle changes in women with polycystic ovary syndrome.

Authors:  Siew S Lim; Samantha K Hutchison; Emer Van Ryswyk; Robert J Norman; Helena J Teede; Lisa J Moran
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28

Review 5.  The Treatment with Complementary and Alternative Traditional Chinese Medicine for Menstrual Disorders with Polycystic Ovary Syndrome.

Authors:  Yuehui Zhang; Xiaozhu Guo; Shuting Ma; Haoyue Ma; Hang Li; Yi Wang; Zhen Qin; Xiaoke Wu; Yaguang Han; Yanhua Han
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-17       Impact factor: 2.629

Review 6.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

7.  Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.

Authors:  Malin Nylander; Signe Frøssing; Caroline Kistorp; Jens Faber; Sven O Skouby
Journal:  Endocr Connect       Date:  2017-01-24       Impact factor: 3.335

Review 8.  Pathophysiology, risk factors, and screening methods for prediabetes in women with polycystic ovary syndrome.

Authors:  Evgenia Gourgari; Elias Spanakis; Adrian Sandra Dobs
Journal:  Int J Womens Health       Date:  2016-08-10

Review 9.  Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.

Authors:  Sebastião Freitas de Medeiros
Journal:  Reprod Biol Endocrinol       Date:  2017-12-08       Impact factor: 5.211

10.  Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Rhiannon K Patten; Russell A Boyle; Trine Moholdt; Ida Kiel; William G Hopkins; Cheryce L Harrison; Nigel K Stepto
Journal:  Front Physiol       Date:  2020-07-07       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.